Note to Sweden: "People with antibodies to Lyme aren't sick"
Kathleen
ca...@drcarolgoodheart.com, lPick...@cdc.gov, Durlan...@yale.edu,
Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, dpr...@stmartin.edu, saint....@sbcglobal.net
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, criminal...@usdoj.gov,
karla.d...@usdoj.gov, christophe...@usdoj.gov,
richar...@yale.edu, harol...@yale.edu, james.p...@yale.edu,
inq...@aldf.com, ly...@idsociety.org, meganm...@theatlantic.com
Subject: Note to Sweden: "People with antibodies to Lyme aren't sick"
Date: Aug 22, 2010 8:27 AM
ARTICLE BELOW
-------------------------
Duh, what part about immunosuppression
[and activation of latents - like the
various herpes viruses - and tolerance
to mycoplasmal infectioun in the blood
and CNS (LYMErix Disease)] associated with
TLR2 agonists don't you get?
At the 1998 FDA meeting on LYMErix,
Vijay Sikand said people with the
high antibody concentration associated
with Steere's HLA-linked disease
are "immune competent. They make
enough antibodies to fight off
the disease."
The reason the HIV vaccine trial
was stopped was because LYMErix-HIV
did not produce antibodies. See
Anthony Fauci, the head of NIAID
talk about it:
http://www.nejm.org/doi/full/10.1056/NEJMp0806162
"The initial empirical approach of immunizing with VaxGen's AIDSVax, a
recombinant form of the outer glycoprotein-120 (gp120) [or LYMErix]
http://www.actionlyme.org/Pam3Cys_Version15.htm
portion of the HIV envelope, which was based on a strategy that was
successful with hepatitis B, failed to protect volunteers from
infection, apparently because the vaccine did not induce broadly
neutralizing antibodies.3"
Too bad the Yale LYMErix Lyme cryme
gang never told anyone LYMErix/gp120
did not prevent Lyme (or tuberculosis).
People with Steere's HLA-linked case
definition (arthritis) aren't sick:
http://www.journals.uchicago.edu/doi/pdf/10.1086/432733
And people who think Steere's HLA-linked case
definition is a "disease" have no clue how
science is done:
http://www.relapsingfever.org
There is no such thing ^^^ as "ROC" in
real science.
KMDickson
http://www.relapsingfever.org
===========================================
http://www.ncbi.nlm.nih.gov/pubmed/20702388
Arch Dis Child. 2010 Aug 10. [Epub ahead of print]
Seroprevalence of Borrelia IgG antibodies among young Swedish children
in relation to reported tick bites, symptoms and previous treatment
for Lyme borreliosis: a population-based survey.
Skogman BH, Ekerfelt C, Ludvigsson J, Forsberg P.
Department of Pediatrics, Falun General Hospital, Falun, Sweden.
Abstract
Background Lyme borreliosis (LB) is the most common tickborne
infection in Sweden and the seroprevalence of Borrelia immunoglobulin
G (IgG) antibodies varies between 2% and 26%. The seroprevalence in
young Swedish children is unknown and the relation to clinical data
has not been previously studied. Objective To determine the
seroprevalence of Borrelia IgG antibodies in serum of young Swedish
children and to relate it to gender, geographical location, reported
tick bites, symptoms and previous treatment for LB. Methods 2000
healthy 5-year-old children (n=2000) were randomly selected from among
participants of a larger prospective population-based study, the ABIS
(All Babies in Southeast Sweden) study. Serum samples were collected
and a Borrelia specific ELISA test (Dako) were performed for IgG
antibody detection. Clinical data were collected from questionnaires
completed by the parents. Results The seroprevalence of Borrelia IgG
antibodies was 3.2% (64/2000). Previous tick bite had been noted in
66% of these seropositive children but the majority (94%) had not
previously been treated for LB. In addition, another 55 children
reported a history of LB but were negative to Borrelia IgG antibodies
in serum. Many of these seronegative children had received treatment
for erythema migrans (n=24), which is a clinical diagnosis. Whether
children were correctly treated or overtreated for LB is however
unknown. No differences in gender, geographical location or reported
tick bites were found when comparing Borrelia-seropositive children
(n=64) and seronegative children with previous LB (n=55). Conclusion
This population-based study demonstrates a Borrelia IgG antibody
seroprevalence of 3.2% in young Swedish children. Very few of these
seropositive children report previous symptoms or treatment for LB.
Thus the findings suggest that exposure to the Borrelia spirochaete
(with subsequent antibody response in serum) does occur in young
children, mostly without giving rise to clinical LB. Future studies on
cell-mediated immune responses are needed to investigate explanatory
immunological mechanisms.
PMID: 20702388 [PubMed - as supplied by publisher]
KMDickson